FATE
Fate Therapeutics Inc
NASDAQ: FATE · HEALTHCARE · BIOTECHNOLOGY
$1.25
+0.81% today
Updated 2026-04-30
Market cap
$154.63M
P/E ratio
—
P/S ratio
23.27x
EPS (TTM)
$-1.15
Dividend yield
—
52W range
$1 – $2
Volume
1.4M
Fate Therapeutics Inc (FATE) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.17M | $2.67M | $971000.00 | $0.00 | $2.43M | $4.40M | $4.11M | $4.74M | $10.68M | $31.43M | $55.85M | $96.30M | $63.53M | $13.63M | $6.65M |
| Revenue growth (YoY) | — | +128.2% | -63.6% | -100.0% | — | +81.1% | -6.7% | +15.4% | +125.3% | +194.3% | +77.7% | +72.4% | -34.0% | -78.5% | -51.2% |
| Cost of revenue | $13.79M | $12.00M | $12.01M | $16.43M | $19.86M | $26.45M | $34.36M | $56.02M | $87.77M | $125.62M | $5.85M | $13.76M | $157.19M | $18.96M | $12.90M |
| Gross profit | $1.17M | $-9.33M | $-11.04M | $-16.43M | $-17.43M | $-22.05M | $-30.25M | $-51.28M | $10.68M | $-94.19M | $50.00M | $96.30M | $-93.65M | $13.63M | $-6.25M |
| Gross margin | 100.0% | -349.4% | -1136.6% | — | -717.0% | -500.9% | -736.8% | -1081.9% | 100.0% | -299.6% | 89.5% | 100.0% | -147.4% | 100.0% | -94.1% |
| R&D | $9.86M | $12.00M | $12.01M | $16.43M | $19.86M | $26.45M | $34.36M | $56.02M | $87.77M | $125.62M | $215.52M | $320.45M | $172.60M | $135.00M | $107.83M |
| SG&A | $4.61M | $4.23M | $6.64M | $8.47M | $10.35M | $9.91M | $11.87M | $15.81M | $23.64M | $33.90M | $57.32M | $84.23M | $81.45M | $74.17M | $46.52M |
| Operating income | $-13.29M | $-13.56M | $-17.68M | $-24.90M | $-27.78M | $-31.96M | $-42.13M | $-67.09M | $-100.73M | $-128.09M | $-216.99M | $-308.39M | $-190.51M | $-210.28M | $-147.70M |
| Operating margin | -1136.2% | -507.8% | -1820.3% | — | -1142.8% | -726.1% | -1025.9% | -1415.4% | -943.1% | -407.5% | -388.6% | -320.2% | -299.9% | -1542.6% | -2222.4% |
| EBITDA | $-12.63M | $-13.16M | $-19.53M | $-24.41M | $-27.09M | $-30.94M | $-40.71M | $-63.70M | $-94.20M | $-125.00M | $-211.14M | $-294.63M | $-172.23M | $-176.58M | $-127.02M |
| EBITDA margin | -1079.3% | -493.0% | -2011.0% | — | -1114.2% | -703.0% | -991.5% | -1343.8% | -882.1% | -397.7% | -378.1% | -305.9% | -271.1% | -1295.4% | -1911.2% |
| EBIT | $-13.30M | $-13.75M | $-20.10M | $-24.90M | $-27.77M | $-31.82M | $-41.68M | $-64.90M | $-96.40M | $-128.09M | $-216.99M | $-308.39M | $-190.51M | $-195.54M | $-136.31M |
| Interest expense | $127000.00 | $487000.00 | $796000.00 | $549000.00 | $2.22M | $1.64M | $1.27M | $1.70M | $1.75M | $2.40M | $4.54M | $5.84M | — | — | — |
| Income tax | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-13.43M | $-14.24M | $-20.89M | $-25.88M | $-29.99M | $-33.46M | $-42.95M | $-66.60M | $-98.15M | $-173.39M | $-212.15M | $-255.06M | $-160.93M | $-186.26M | $-136.31M |
| Net income growth (YoY) | — | -6.0% | -46.7% | -23.9% | -15.9% | -11.6% | -28.4% | -55.1% | -47.4% | -76.7% | -22.4% | -20.2% | +36.9% | -15.7% | +26.8% |
| Profit margin | -1147.6% | -533.3% | -2151.8% | — | -1233.7% | -760.2% | -1046.1% | -1405.0% | -919.0% | -551.6% | -379.9% | -264.9% | -253.3% | -1366.5% | -2051.1% |